Loading... (0%)
About liver disease

Analyst Coverage

The analysts below follow GENFIT. The opinions, projections or forecasts made by the financial analysts regarding the performance of GENFIT are the sole responsability of their authors and do not represent the opinions, projections or forecasts of GENFIT or its management. Furthermore, GENFIT provides no assurance with regard to the accuracy or correctness of such information. GENFIT has no control over the content, quality, nature or reliability of any such analyst reports, and shall have no liability whatsoever in respect of the information provided. The information provided below is for information purposes only and is not intended to imply any endorsement of GENFIT or to provide any investment advice. This list does not purport to be complete, correct or representative as of any point in time.

ANALYST

RATING

B. RILEY FBR
Mayank Mamtani

June 25, 2019
Buy
Target Price: $52

BARCLAYS CAPITAL Inc.
Geoff Meacham

June 24, 2019
Overweight
Target Price: $55

H.C. WAINWRIGHT & CO.
Ed Arce

July 26, 2019
Buy
Target Price: $72

ROTH CAPITAL PARTNERS
Yasmeen Rahimi

July 26, 2019
Buy
Target Price: €112

SVB LEERINK
Pasha Sarraf

June 24, 2019
Outperform
Target Price: $58

BRYAN, GARNIER & CO
Jean-Jacques Le Fur

July 26, 2019
Buy
Target Price: €65

CM-CIC SECURITIES
Fanny Meindre

July 15, 2019
Current value: €48
Forecasted value: €169

KEMPEN & CO
Suzanne van Voorthuizen

June 25, 2019
Buy
Target Price: €42

KEPLER CHEUVREUX
Arsene Guekam

June 25, 2019
Buy
Target Price: €48

ODDO BHF
Pierre Corby

July 29, 2019
Buy
Target Price: €55

PORTZAMPARC
Christophe Dombu

June 25, 2019
Buy
Target Price: €60,10

 
venenatis, lectus elit. elementum sit et, mi, sed